Phase II Exploratory Study of Immune Responses in Patients With Metastatic Melanoma Treated With Mouse Monoclonal Anti-OX40
Latest Information Update: 07 Nov 2021
At a glance
- Drugs MEDI 6469 (Primary)
- Indications Malignant melanoma
- Focus Pharmacodynamics
Most Recent Events
- 01 Sep 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
- 17 Aug 2011 New trial record